CRISPR-AaCas12b Assay: Clinical Validation for Tuberculosis and Drug-Resistance Detection

A validation dataset for a multiplex CRISPR-Cas diagnostic assay targeting Mycobacterium tuberculosis and multidrug-resistant tuberculosis mutations. The data includes performance metrics from 48 clinical samples, with sensitivity and specificity results for detecting MTB and mutations rpoB 1349C>T and katG 944G>C. The dataset was authored by Yujiao Hu and last updated on 2026-05-19.

Use Cases

• Benchmarking new diagnostic assays based on reported sensitivity (97.1%) and specificity (100%) for MTB detection.
• Evaluating rapid molecular test workflows based on the described 30-35 minute total turnaround time.
• Studying the detection of specific drug-resistance mutations (rpoB 1349C>T, katG 944G>C) associated with MDR-TB.
• Comparing dual-readout signal detection methods (fluorescent platform and lateral flow chromatography) for diagnostic accuracy.

Strengths

• Reported high diagnostic sensitivity (97.1%) and specificity (100%) for MTB detection against a culture reference standard.
• Validation includes 48 clinical samples with comparisons to WHO-recommended GeneXpert MTB/RIF and sequencing standards.
• Assay demonstrates a low limit of detection (1.5 CFU/mL) for Mycobacterium tuberculosis.

Limitations

• Row count and specific column-level documentation are absent; field semantics must be inferred after download.
• The dataset is small (838.9 KB), indicating limited scope, likely containing summary validation results rather than raw experimental data.

Provenance

Source

Yujiao Hu

Collection Method

Clinical validation of a multiplex-recombinase polymerase amplification (RPA) coupled CRISPR-AaCas12b assay.

Freshness

Last updated 2026-05-19 05:29:13; freshness should be verified.